Quintrio
Home

Stock overview

Nyxoah SA Ordinary Shares

NYXH

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Last trade $0.8829
Day change -$0.0108 (-1.21%)
Day range $0.883 – $0.906
Volume 18,575
Market cap $91M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for NYXH.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for NYXH.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

INSP Is Up 12.1% in Three Months: Can Its Rally Continue From Here?

Inspire Medical Systems (INSP) shares gained 12.1% over three months despite a 7.9% revenue decline and 62.2% drop in adjusted Q3 EPS. Reimbursement issues cost the company $30M in Q3 revenues with a projected $120M full-year 2026 impact. The company targets low-single-digit revenue growth in 2027 through Project Horizon and battery replacement procedures, though reimbursement execution remains a key risk factor.

Zacks Investment Research

Nyxoah SA (NYXH) Reports Q3 Loss, Lags Revenue Estimates

Nyxoah SA (NYXH) reported a quarterly loss of $0.2 per share, beating consensus estimates of $0.24 loss, with a 16.67% earnings surprise. However, revenues of $10.55 million missed estimates by 5.02%. The stock has declined 81.3% year-to-date versus the S&P 500's 12.3% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.

Zacks Investment Research

Tempus AI (TEM) Beats Q3 Earnings and Revenue Estimates

Tempus AI (TEM) reported quarterly earnings of $0.07 per share, beating consensus estimates of a loss of $0.09, representing a 177.78% earnings surprise. The company posted revenues of $411.54 million, surpassing estimates by 0.05% and showing year-over-year growth from $334.21 million. However, the stock received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market. The Medical Info Systems industry ranks in the top 36% of Zacks industries.

GlobeNewswire Inc.

Nyxoah Announces Preliminary Results for the Third Quarter of 2026 and Adjusts Revenue Guidance for 2026

Nyxoah reported Q3 2026 global net revenue of €9.2 million with 29% sequential U.S. growth, but lowered full-year 2026 revenue guidance to €33-35 million from €36-40 million. The company submitted a PMA supplement to expand its Genio hypoglossal nerve stimulation system to Complete Concentric Collapse patients, with the ACCCESS study meeting efficacy endpoints at 77.2% AHI responder rate.

GlobeNewswire Inc.

Nyxoah Annonce ses Résultats Préliminaires pour le Troisième Trimestre 2026 et Ajuste ses Prévisions de Chiffre d’Affaires pour 2026

Nyxoah reported Q3 2026 net revenue of €9.2 million with 29% sequential growth in US sales. The company submitted a PMA supplement to the FDA to expand Genio's indication to complete concentric collapse patients, with the ACCCESS study meeting primary efficacy endpoints (77.2% responder rate). However, full-year 2026 revenue guidance was lowered to €33-35 million from €36-40 million.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.